Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Ionis Pharmaceuticals
Biotech
The 'diabolical' molecule set to become biotech's next gold rush
Should medicines that lower Lp(a) reach their full potential, they could spark a craze rivaling obesity and even surpass the success of statins.
Darren Incorvaia
Apr 9, 2026 8:00am
Ionis scraps Alzheimer's candidate for people with Down syndrome
Feb 20, 2026 1:50pm
GSK's 'functional cure' for hep B proves worth in ph. 3 trials
Jan 7, 2026 6:15am
Ionis rare disease candidate ekes out phase 3 win
Sep 22, 2025 10:46am
Arrowhead sues Ionis over patent dispute for Tryngolza rival
Sep 11, 2025 11:33am
RNA biotech emerges with $52M and clinical rare disease asset
Aug 25, 2025 10:13am
